A Prospective, Open-label Study To Assess The Pharmacokinetics, Safety & Efficacy Of Anidulafungin When Used To Treat Children With Invasive Candidiasis, Including Candidemia

Trial Profile

A Prospective, Open-label Study To Assess The Pharmacokinetics, Safety & Efficacy Of Anidulafungin When Used To Treat Children With Invasive Candidiasis, Including Candidemia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Anidulafungin (Primary) ; Fluconazole
  • Indications Candidaemia; Candidiasis
  • Focus Adverse reactions; Registrational
  • Sponsors Pfizer
  • Most Recent Events

    • 06 Jan 2016 Planned primary completion date changed from 1 May 2019 to 1 Jun 2019 as reported by ClinicalTrials.gov.
    • 09 Dec 2015 Planned End Date changed from 1 Jun 2016 to 1 Jun 2019 as reported by ClinicalTrials.gov.
    • 09 Dec 2015 Planned primary completion date changed from 1 Jun 2016 to 1 May 2019 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top